Field cancerization or field effect (also termed field change, field change cancerization, field carcinogenesis, cancer field effect or premalignant field defect) is a biological process in which large areas of cells at a tissue surface or within an organ are affected by carcinogenic alterations. The process arises from exposure to an injurious environment, often over a lengthy period.
The initial step in field cancerization is associated with various molecular lesions such as acquired genetic mutations and epigenetic changes, occurring over a widespread, multi-focal "field". These initial molecular changes may subsequently progress to cytologically recognizable premalignant foci of dysplasia, and eventually to carcinoma in situ (CIS) or cancer. The image of a longitudinally opened colon resection on this page shows an area of a colon resection that likely has a field cancerization or field defect. It has one cancer and four premalignant polyps. Field cancerization can occur in any tissue. Prominent examples of field cancerization include premalignant field defects in head and neck cancer, lung cancer, colorectal cancer, Barrett's esophagus, skin, breast ducts and bladder. Field cancerization has implications for cancer surveillance and treatment. Despite adequate resection and being histologically normal, the remaining locoregional tissue has an increased risk for developing multiple independent cancers, either synchronously or metachronously.
A common carcinogenic alteration, found in many cancers and in their adjacent field defects from which the cancers likely arose, is reduced expression of one or more DNA repair enzymes. Since reduced DNA repair expression is often present in a field cancerization or a field defect, it is likely to have been an early step in progression to the cancer.
| Colorectal | MGMT | 46% | 34% | [1] | |
|---|---|---|---|---|---|
| Colorectal | MGMT | 47% | 11% | [2] | |
| Colorectal | MGMT | 70% | 60% | [3] | |
| Colorectal | MSH2 | 13% | 5% | ||
| Colorectal | ERCC1 | 100% | 40% | [4] | |
| Colorectal | PMS2 | 88% | 50% | ||
| Colorectal | XPF | 55% | 40% | ||
| Head and Neck | MGMT | 54% | 38% | [5] | |
| Head and Neck | MLH1 | 33% | 25% | [6] | |
| Head and Neck | MLH1 | 31% | 20% | [7] | |
| Stomach | MGMT | 88% | 78% | [8] | |
| Stomach | MLH1 | 73% | 20% | [9] | |
| Esophagus | MLH1 | 77%-100% | 23%-79% | [10] |
Field defects associated with gastrointestinal tract cancers also commonly displayed reduced apoptosis competence, aberrant proliferation and genomic instability.[11] Field defects of the gastrointestinal tract that show those common faults occurred in the oropharynx, esophagus, stomach, bile duct, pancreas, small intestine and colon/rectum.
The field defect adjacent to a colon cancer consists of the inner surface of the colon (the epithelium) that has about 1 million crypts (indentations in the surface of the epithelium). Each crypt has about 5,000 cells in the shape of a test-tube and all 5,000 cells of the crypt are generated from the few stem cells at the base of the crypt. The stem cells at the base of the crypt can undergo "crypt conversion" where a stem cell with a selective advantage takes over the stem cell niche, and all cells of that crypt display consistent expression (high or low) of a protein being evaluated.
The diagram shows results obtained by Facista et al. A particular colon resection from a colon cancer patient was evaluated for expression of 3 different DNA repair enzymes: Ku86 (active in the non-homologous end joining pathway), ERCC1 (active in the nucleotide excision DNA repair pathway) and PMS2 (active in the mismatch DNA repair pathway). The percent of crypts in 6 tissue samples taken within the field defect were evaluated for frequency of high levels of expression of each of the repair proteins. Almost every crypt in all tissue samples from this patient showed high expression of KU86. However, the majority of crypts in all 6 tissue samples were reduced or absent in protein expression of ERCC1 and PMS2. The crypts with reduced or absent expression of ERCC1 or PMS2 usually occurred in large patches of adjacent crypts. Both ERCC1 and PMS2, in these tissue samples, were thought to be deficient due to epigenetic alterations.
10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q . Slaughter . D. P. . Southwick . H. W. . Smejkal . W. . Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin . Cancer . 6 . 5 . 963–968 . 1953 . 13094644. free .
Braakhuis . B. J. M. . Brakenhoff . R. H. . Leemans . C. R. . 10.1634/theoncologist.10-7-493 . Second Field Tumors: A New Opportunity for Cancer Prevention? . The Oncologist . 10 . 7 . 493–500 . 2005 . 16079316 . free .
Field cancerization and local relapse.. Leemans. CR. Braakhuis, BJM . Brakenhoff RH. . January 2011. Nature Reviews Cancer . 11. 1. 9–22 . 10.1038/nrc2982. 21160525.